Instituto de Investigación Biomédica de Salamanca-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2022

  1. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  2. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  2. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  3. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

  2. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers

    Journal of Immunological Methods, Vol. 475

2016

  1. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

    Blood, Vol. 127, Núm. 4, pp. 420-425

2015

  1. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2014

  1. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

    Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773

  2. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

    Haematologica, Vol. 98, Núm. 1, pp. 79-86

  2. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

  3. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

  2. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611